Imagine a world where we could target and destroy cancer cells with precision, leaving healthy cells unharmed. Sounds like science fiction, right? But groundbreaking research from the University of Osaka and MIT has brought us one step closer to this reality.
In a fascinating study, scientists have uncovered a hidden partnership between two motor proteins, KIF18A and CENP-E, that plays a critical role in chromosome alignment during cell division. Think of it like a perfectly choreographed dance: these proteins work together to ensure chromosomes line up correctly at the center of the cell. When this process, called chromosome congression, goes awry, it can lead to chromosomal instability, a hallmark of cancer.
And this is the part most people miss: the researchers discovered that simultaneously blocking both KIF18A and CENP-E selectively kills cancer cells, leaving healthy cells largely unaffected. This finding opens up exciting possibilities for developing more targeted and effective cancer treatments.
But here's where it gets controversial: the study suggests that cancer cells with naturally low levels of CENP-E are particularly vulnerable to drugs targeting KIF18A. This raises the question: could measuring CENP-E levels in tumors become a way to predict which patients will respond best to these new therapies?
The research team cleverly used a unique approach, employing a genome-wide CRISPR screen in cells with a weakened kinetochore (the cellular structure responsible for chromosome attachment) caused by a CENP-C mutation. This allowed them to identify KIF18A as a crucial player in chromosome alignment, working in tandem with CENP-E downstream of CENP-C.
Further investigation revealed a fascinating compensatory mechanism: in healthy cells, if one of these proteins is compromised, the other can often step in to maintain proper chromosome alignment. However, when both proteins are impaired, the system collapses, leading to cell death. This delicate balance highlights the precision required for successful cell division and the potential vulnerabilities that can be exploited in cancer treatment.
Should we be optimistic about the potential of targeting these proteins for cancer therapy? While the results are promising, further research is needed to fully understand the complexities of this mechanism and its applicability to different types of cancer. What are your thoughts?
As Tatsuo Fukagawa, the study's senior author, emphasizes, this research not only sheds light on the intricate mechanisms of chromosome segregation but also demonstrates the power of basic research in driving the development of targeted cancer therapies.
Source:
Miao, J., et al. (2025) KIF18A promotes chromosome congression in cooperation with CENP-E downstream of CENP-C. Cell Reports. DOI: 10.1016/j.celrep.2025.116515.
Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
